Shoulder Innovations enters its May 12 earnings report with a freshly upgraded price target and a stock that needs to prove its growth story can survive mounting operating losses.
The most timely signal heading into the print comes from the analyst community. Piper Sandler reiterated its Overweight rating yesterday and lifted its target to $19 from $18 — the only analyst action within the past two weeks, and a constructive one. The consensus remains firmly bullish, with all covering analysts holding buy-equivalent ratings and a mean target around $20.50, implying roughly 55% upside from the current $13.20 close. The bull thesis is tangible: 58% revenue growth in fiscal 2025, surgeon adoption running above 60% year-over-year, and management guiding toward $45–$46 million in 2025 sales after raising the outlook. Bears counter with real numbers too — an adjusted EBITDA loss of $7.5 million, ballooning SG&A from headcount and legal costs, and a total EBITDA loss of $23.6 million that raises questions about when the growth converts to anything resembling profitability.
The lending market offers no alarm bells. Short interest is a modest 2.1% of the free float, down roughly 5% over the past month after a brief spike in early April. The borrow market is equally relaxed — cost to borrow runs just above 1%, well off the 1.45% levels seen in mid-April, and availability remains loose enough to offer no meaningful squeeze dynamics. The ORTEX short score of 50 sits squarely at the midpoint of the 0–100 range, signalling no particular directional conviction from short sellers. Taken together, the short side of the ledger looks neutral rather than charged.
The insider picture adds a layer of quiet confidence. In March, both the CEO and CFO bought shares in the open market — small in dollar terms ($33K and $30K respectively) but notable for the timing, with the stock then trading around $15. That cluster continued a pattern established in December, when the CEO made multiple purchases. Net insider buying reached over 12,000 shares in the 90-day window through March 13. The stock has since slipped about 12% to $13.20, making those insider buys currently underwater, which raises the stakes for the Q1 print to provide a catalyst.
The May 12 release is therefore less a test of whether Shoulder Innovations can grow revenue and more a test of whether it can narrow losses fast enough to keep its bullish analyst consensus intact at a price-to-book ratio that has compressed nearly 13% over the past month.
See the live data behind this article on ORTEX.
Open SI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
